wael fayad  enumeral biomedical holdings inc  zoominfocom security check required facebookjoin or log into facebook   email or phonepasswordforgot accountlog indo you want to join facebooksign upsign upsecurity checkplease enter the text belowcant read the text abovetry another text or an audio captchatext in the boxwhats thissecurity checkthis is a standard security test that we use to prevent spammers from creating fake accounts and spamming userssubmitenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version enumeral appoints wael fayad as chairman president and chief executive officer  business wire enumeral appoints wael fayad as chairman president and chief executive officer september    am eastern daylight time cambridge massbusiness wireenumeral biomedical holdings inc otcqbenum “enumeral” or the “company” a biotechnology company focused on the discovery and development of novel antibodybased immunotherapies to help the immune system fight cancer and other diseases today announced that wael fayad has been appointed chairman president and chief executive officer of the company effective as of september   mr fayad brings to enumeral more than two decades of senior executive and business development experience in the life sciences industry from  to  mr fayad held positions of increasing responsibility at forest laboratories inc most recently as corporate vice president global business development in that role he was responsible for business development and alliance management including the identification assessment and negotiation of multiple business opportunities mr fayad helped build and manage a broad network of partnerships at forest and upon forest’s acquisition by actavis mr fayad also assisted with the integration of the two companies mr fayad was subsequently engaged in a number of entrepreneurial ventures including helping to launch vc pharmaceuticals a startup company focusing on improving healthcare outcomes and reducing the total cost of care mr fayad continues to serve on vc pharmaceuticals’ advisory board prior to forest mr fayad served in positions of increasing responsibility at scheringplough and novartis in the fields of sales marketing and new product development mr fayad holds a bs in biology from the american university of beirut and an mba from concordia university in connection with mr fayad’s appointment as chairman president and chief executive officer john j rydzewski stepped down as enumeral’s executive chairman and from the company’s board of directors arthur h tinkelenberg phd enumeral’s former president and chief executive officer also stepped down from the company’s board of directors “i am very excited to join enumeral a company with distinguished science in the fields of immunooncology and the immune response to disease” said mr fayad “i am especially encouraged by the progress enumeral has made in building and validating its platform and advancing highly differentiated programs i look forward to further harnessing the power of enumeral’s platform and to accelerating the company’s evolution to advance treatments that meet compelling patient needs in cancer and other diseases” “we are particularly pleased to have wael lead enumeral as chairman and chief executive officer and we thank art and john for their many contributions since the company’s founding” said robert van nostrand the company’s lead independent director “we are now embarking on a new chapter in enumeral’s history as we seek to further advance the company’s core platform capabilities and antibody drug discovery efforts” “wael is a life sciences industry veteran with a deep network of commercial relationships that can help to unlock the value of enumeral’s platform” said allan rothstein a member of the company’s board of directors “wael clearly recognizes our company’s potential which itself is further validation of what we have built at enumeral” about enumeral enumeral is a biopharmaceutical company focused on discovering and developing novel antibodybased immunotherapies to help the immune system fight cancer and other diseases the company is building a pipeline focused on nextgeneration checkpoint modulators with initial targets including pd tim lag ox tigit and vista in developing these molecules enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells this provides key insights for drug candidate selection and target validation for more information on enumeral please visit wwwenumeralcom forward looking statements disclosure this press release contains certain “forwardlooking statements” within the meaning of the private securities litigation reform act of  as amended such statements reflect current beliefs of enumeral biomedical holdings inc “enumeral” with respect to future events and involve known and unknown risks uncertainties and other factors affecting operations market growth enumeral’s stock price services products and licenses no assurances can be given regarding the achievement of future results and although enumeral believes that the expectations reflected in these forwardlooking statements are based on reasonable assumptions actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events factors that may cause actual results performance or achievements or industry results to differ materially from those contemplated by such forwardlooking statements include among others the risks that a enumeral’s expectations regarding market acceptance of the company’s business in general and the company’s ability to penetrate the antibody discovery and development fields in particular as well as the timing of such acceptance b enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies c the scope validity and enforceability of enumeral’s and third party intellectual property rights d enumeral’s ability to raise capital when needed and on acceptable terms and conditions e enumeral’s ability to comply with governmental regulation f the intensity of competition g changes in the political and regulatory environment and in business and fiscal conditions in the united states and overseas and h general economic conditions more detailed information about enumeral and risk factors that may affect the realization of forwardlooking statements including forwardlooking statements in this press release is set forth in enumeral’s filings with the securities and exchange commission enumeral urges investors and security holders to read those documents free of charge at the commission’s website at httpwwwsecgov forwardlooking statements speak only as to the date they are made and except for any obligation under the us federal securities laws enumeral undertakes no obligation to publicly update any forwardlooking statement as a result of new information future events or otherwise contacts enumeral biomedical holdings inckevin sarney 7kevinenumeralcom contacts enumeral biomedical holdings inckevin sarney 7kevinenumeralcom search advanced news search advanced news search log in sign up wael fayad  former vice presidentglobal business development at forest laboratories inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink wael fayad former vice presidentglobal business development at forest laboratories inc overview in the news relationships paths education career history boards  committees nonprofit donations  grants political donations public holdings transactions wael fayad former vice presidentglobal business development at forest laboratories inc overview age  born 7 notable companies enumeral biomedical holdings inc board seats  number of relationships this person is connected to 2 people in the news see more business wire april   enumeral and icav to pursue infectious disease collaboration business wire march   enumeral reports year end  financial results business wire december 2  enumeral completes successful warrant tender offer and receives  million in gross proceeds business wire november   enumeral reports third quarter financial results business wire september   enumeral appoints wael fayad as chairman president and chief executive officer relationships see details kevin g sarney president chief executive officer treasurer director  cao at enumeral biomedical holdings inc john j rydzewski former manager at price waterhouse llp robert l van nostrand chief financial officer agi dermatics at estee lauder cos inc robert j easton cochairman at bionest partners sas paul sekhri president  chief executive officer at lycera corp allan p rothstein professional at hedge capital partners llc barry c buckland head bioprocess development at protein sciences corporation arthur h tinkelenberg cofounder at enumeral biomedical holdings inc daniel b wolfe president chief financial officer  chief compliance officer at harris  harris group olesya didenko former president chief executive officer chief financial officer secretary  treasurer at enumeral biomedical holdings inc see  more listings with relsci professional start my free trial ➤ see  more paths to wael fayad wael fayad you connections via relationship science wael fayad sync your contacts to see how you can connect with wael fayad start my free trial ➤ see more educational background   american university of beirut the american university of beirut is a private secular and independent university in beirut lebanon degrees awarded at the american university of beirut aub are officially registered with the new york board of regents on april 2  the state of new york granted a charter for the syrian protestant college the college which was renamed the american university of beirut in 2 opened on december     concordia university those who want options in their higher learning experience might find concordia university cu in portland oregon a great choice for college cu students are given the flexibility to learn in a campus classroom environment on the internet or in study abroad programs the school presents credit for short two weeks and longterm one year academic experiences on most continents around the world this is a great way for students to become worldly and gain knowledge of different cultures cu is a smaller private christian university they offer students access to bible review groups campus church services and religious retreats the school has undergraduate and graduate programs in exercise and sport science nursing and social work they also have the same type of academic degree programs online for those who want to pursue degrees in areas such as theological studies teaching and business administration the university can provide monetary assistance to those who qualify and they extend a special offer to students those who completely fill out the fafsa forms can earn  or some other type of financial aid from the school just for applying most of the population at cu is receiving some type of financial support if you are looking for variety in your academic experience in a christian college environment concordia university might be the right place for you career history vice presidentglobal business development tenure unconfirmed forest laboratories inc forest has wellestablished franchises in multiple therapeutic areas and we are always exploring new product opportunities that address a range of health conditions our principal brands include bystolic® nebivolol daliresp® roflumilast lexapro® escitalopram oxalate linzess™ linaclotide namenda® memantine hcl savella®milnacipran hcl teflaro® ceftaroline fosamil for injection tudorza™ pressair™ aclidinium bromide inhalation powder and viibryd® vilazodone hcl forest identifies develops and delivers pharmaceutical products that make a difference in peoples lives we have been extremely successful in meeting our business objectives and expanding our franchises but we also derive satisfaction in helping to bring relief to people who are suffering we credit our success to our innovation integrity and commitment to developing important products chairman president  chief executive officer   prior enumeral biomedical holdings inc enumeral biomedical holdings inc is a biopharmaceutical company which is engaged in the discovery and development of novel antibody immunotherapies for the treatment of cancer and other diseases it uses a humandriven immunoprofiling platform to identify and validate potential drug candidates in human immune microenvironments the company was founded by barry c buckland john j rydzewski arthur h tinkelenberg in 2 and is headquartered in cambridge ma boards  committees corporate boards ▾ chairman board of directors   current enumeral biomedical holdings inc enumeral biomedical holdings inc is a biopharmaceutical company which is engaged in the discovery and development of novel antibody immunotherapies for the treatment of cancer and other diseases it uses a humandriven immunoprofiling platform to identify and validate potential drug candidates in human immune microenvironments the company was founded by barry c buckland john j rydzewski arthur h tinkelenberg in 2 and is headquartered in cambridge ma nonprofit donations  grants   2 direct relief international direct relief international inc provides medical assistance to improve the quality of life for people affected by poverty disaster and civil unrest at home and throughout the world direct relief works to support the work of healthcare providers equipping them with the medicines supplies and equipment the company is headquartered in santa barbara ca political donations 2 2 charles boustany partner at capitol counsel llc public holdings restricted data only for relsci professional users start my free trial ➤ see more transactions details hidden enumeral biomedical holdings inc raised money in a private placement transaction details hidden enumeral biomedical holdings inc raised money in a private placement transaction other affiliations wael fayad is affiliated with forest laboratories inc enumeral biomedical holdings inc enumeral biomedical holdings inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ enumeral appoints wael fayad as chairman president and chief executive officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in 7 minssp 272 dow  nasdaq7 enumeral appoints wael fayad as chairman president and chief executive officerbusiness wireseptember  reblogsharetweetsharecambridge massbusiness wireenumeral biomedical holdings inc enum “enumeral” or the “company” a biotechnology company focused on the discovery and development of novel antibodybased immunotherapies to help the immune system fight cancer and other diseases today announced that wael fayad has been appointed chairman president and chief executive officer of the company effective as of september  mr fayad brings to enumeral more than two decades of senior executive and business development experience in the life sciences industry from  to  mr fayad held positions of increasing responsibility at forest laboratories inc most recently as corporate vice president global business development in that role he was responsible for business development and alliance management including the identification assessment and negotiation of multiple business opportunities mr fayad helped build and manage a broad network of partnerships at forest and upon forest’s acquisition by actavis mr fayad also assisted with the integration of the two companies mr fayad was subsequently engaged in a number of entrepreneurial ventures including helping to launch vc pharmaceuticals a startup company focusing on improving healthcare outcomes and reducing the total cost of care mr fayad continues to serve on vc pharmaceuticals’ advisory board prior to forest mr fayad served in positions of increasing responsibility at scheringplough and novartis in the fields of sales marketing and new product development mr fayad holds a bs in biology from the american university of beirut and an mba from concordia universityin connection with mr fayad’s appointment as chairman president and chief executive officer john j rydzewski stepped down as enumeral’s executive chairman and from the company’s board of directors arthur h tinkelenberg phd enumeral’s former president and chief executive officer also stepped down from the company’s board of directors“i am very excited to join enumeral a company with distinguished science in the fields of immunooncology and the immune response to disease” said mr fayad “i am especially encouraged by the progress enumeral has made in building and validating its platform and advancing highly differentiated programs i look forward to further harnessing the power of enumeral’s platform and to accelerating the company’s evolution to advance treatments that meet compelling patient needs in cancer and other diseases”“we are particularly pleased to have wael lead enumeral as chairman and chief executive officer and we thank art and john for their many contributions since the company’s founding” said robert van nostrand the company’s lead independent director “we are now embarking on a new chapter in enumeral’s history as we seek to further advance the company’s core platform capabilities and antibody drug discovery efforts”“wael is a life sciences industry veteran with a deep network of commercial relationships that can help to unlock the value of enumeral’s platform” said allan rothstein a member of the company’s board of directors “wael clearly recognizes our company’s potential which itself is further validation of what we have built at enumeral”about enumeralenumeral is a biopharmaceutical company focused on discovering and developing novel antibodybased immunotherapies to help the immune system fight cancer and other diseases the company is building a pipeline focused on nextgeneration checkpoint modulators with initial targets including pd tim lag ox tigit and vista in developing these molecules enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells this provides key insights for drug candidate selection and target validation for more information on enumeral please visit wwwenumeralcomforward looking statements disclosurethis press release contains certain “forwardlooking statements” within the meaning of the private securities litigation reform act of  as amended such statements reflect current beliefs of enumeral biomedical holdings inc “enumeral” with respect to future events and involve known and unknown risks uncertainties and other factors affecting operations market growth enumeral’s stock price services products and licenses no assurances can be given regarding the achievement of future results and although enumeral believes that the expectations reflected in these forwardlooking statements are based on reasonable assumptions actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events factors that may cause actual results performance or achievements or industry results to differ materially from those contemplated by such forwardlooking statements include among others the risks that a enumeral’s expectations regarding market acceptance of the company’s business in general and the company’s ability to penetrate the antibody discovery and development fields in particular as well as the timing of such acceptance b enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies c the scope validity and enforceability of enumeral’s and third party intellectual property rights d enumeral’s ability to raise capital when needed and on acceptable terms and conditions e enumeral’s ability to comply with governmental regulation f the intensity of competition g changes in the political and regulatory environment and in business and fiscal conditions in the united states and overseas and h general economic conditionsread moremore detailed information about enumeral and risk factors that may affect the realization of forwardlooking statements including forwardlooking statements in this press release is set forth in enumeral’s filings with the securities and exchange commission enumeral urges investors and security holders to read those documents free of charge at the commission’s website at httpwwwsecgov forwardlooking statements speak only as to the date they are made and except for any obligation under the us federal securities laws enumeral undertakes no obligation to publicly update any forwardlooking statement as a result of new information future events or otherwiseview source version on businesswirecom httpwwwbusinesswirecomnewshome77enreblogsharetweetsharerecently viewedyour list is emptywhat to read nextwind projects in peril as indian states rethink purchasesbloombergengineer finds pattern makes millions in stocksmoney morningsponsoredamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediamy next car is electrified says shell ceoautoblogmeg whitman rules out becoming uber ceo reaffirms commitment to hpecnbcdiscover it  out of  avg by 2k customersdiscover cardsponsoredwhat you need to know on wall street todaybusiness insiderthe real reason overseas manufacturing is coming to americayahoo financethe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderzuckerberg wifes ambitious secret finally exposedunewzmesponsoredtax cuts just got more likelyyahoo financechevron and exxon mobil have a tough path ahead nyse traderyahoo finance videoblue apron delivers bullish calls this weekyahoo finance mustown stocks in banyan hillsponsoredtodays charts dont get blindsided by teslas shiny new model yahoo financethe 7 most profitable markets for home sellerscreditcomcolbert says f—k you to trump disgusted by transgender military bansharenow you can say it to me too im a veteran and i know of the difficulties that can happen people have to know the truth of what it like in the military having women in combat situations has gotten people killed but no one wants to talk about it sex discrimination has become more common in the military courts i wish people could understand these conflicts of morale i have nothing against anyone with different lifestyles but we have to recognize the dangersjoin the conversation  k